Overview

Belimumab In Treatment of Early Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and impact on B cell subsets of belimumab in early SLE patients(disease duration less than 3 months).
Phase:
Phase 4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Belimumab